NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
Loading market information…
NSE · TORNTPHARM.NS · INR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Torrent Pharmaceuticals Limited’s forward annual dividend is ₹18.00 per share, paid semi-annual. The forward yield is 0.39% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Torrent Pharmaceuticals Limited’s next earnings report is currently expected on Jan 28, 2027, with estimated earnings per share of ₹15.45. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Torrent Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2026 | Jul 28, 2025 | ₹16.35-6.09% vs estimate | ₹31.78B+0.82% vs estimate |
|---|
| Q4 2025 | May 20, 2025 | ₹15.35+7.34% vs estimate | ₹29.50B-1.38% vs estimate |
|---|
| Q3 2025 | Jan 24, 2025 | ₹14.90-1.19% vs estimate | ₹28.09B-5.79% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
₹1,184.40+₹8.90 (+0.76%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 3.87% below the high.
₹1,345.00+₹9.60 (+0.72%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
₹1,358.00-₹7.60 (-0.56%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 14.77% below the high.
₹2,469.30-₹20.70 (-0.83%)
Mankind Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 6.54% below the high.
₹1,659.90+₹15.10 (+0.92%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 4.6% below the high.
₹1,989.90+₹17.20 (+0.87%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 21.33% below the high.
₹5,079.00+₹9.00 (+0.18%)
Alkem Laboratories Limited’s quoted price sits in the lower half of its reported 52-week range, 14.4% below the high.
